COMPASS PATHW SP.ADR (5Y6) - Cash Flow Conversion Efficiency
Based on the latest financial reports, COMPASS PATHW SP.ADR (5Y6) has a cash flow conversion efficiency ratio of -0.477x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-40.31 Million ≈ $-47.12 Million USD) by net assets (€84.53 Million ≈ $98.83 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see COMPASS PATHW SP.ADR (5Y6) total market value for the company's overall valuation and market capitalisation.
COMPASS PATHW SP.ADR - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how COMPASS PATHW SP.ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
COMPASS PATHW SP.ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of COMPASS PATHW SP.ADR ranked by their cash flow conversion efficiency. Explore 5Y6 cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IRESS LTD
F:BRF
|
N/A |
|
Everlight Chemical Industrial Corp
TW:1711
|
0.045x |
|
IntelliEPI Cayman
TWO:4971
|
0.015x |
|
Cromwell Property Group
AU:CMW
|
0.023x |
|
Shenzhen TXD Technology Co Ltd
SHE:002845
|
-0.017x |
|
Hebei Huijin Electromechanical Co Ltd
SHE:300368
|
-0.047x |
|
Ciputra Development Tbk
JK:CTRA
|
0.004x |
|
Liberty Broadband Srs A
NASDAQ:LBRDA
|
-0.012x |
Annual Cash Flow Conversion Efficiency for COMPASS PATHW SP.ADR (2021–2025)
The table below shows the annual cash flow conversion efficiency of COMPASS PATHW SP.ADR from 2021 to 2025. View COMPASS PATHW SP.ADR share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €-52.85 Million ≈ $-61.78 Million |
€-157.24 Million ≈ $-183.83 Million |
2.975x | +486.18% |
| 2024-12-31 | €154.69 Million ≈ $180.85 Million |
€-119.19 Million ≈ $-139.34 Million |
-0.770x | -78.61% |
| 2023-12-31 | €225.74 Million ≈ $263.92 Million |
€-97.38 Million ≈ $-113.84 Million |
-0.431x | +25.85% |
| 2022-12-31 | €181.28 Million ≈ $211.94 Million |
€-105.45 Million ≈ $-123.28 Million |
-0.582x | -144.21% |
| 2021-12-31 | €284.41 Million ≈ $332.51 Million |
€-67.75 Million ≈ $-79.20 Million |
-0.238x | -- |
About COMPASS PATHW SP.ADR
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as … Read more